Catalyst Wire Dossier Catalyst Wire Dossier

Janus-associated kinase (JAK) inhibitor

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Janus-associated kinase (JAK) inhibitor, covering 2012-05-30 to 2012-05-30. Get the full timeline:

Most recent: Clinical Trial Update: Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial [Phase 3]

See pricing